Category: Latest News
-
Drone Backlog and Defense Expansion Drive AIRO’s 2026 Growth Outlook Despite Q1 Losses
AIRO reiterated its full-year revenue growth forecast as the company expands its AI-enabled drone portfolio and builds a defense backlog exceeding $150 million. Key Investor Takeaways Why AIRO Stock Is in Focus AIRO reported first-quarter 2026 revenue of $8.9 million, down from $11.8 million in the same period last year. Gross profit declined to $2.4…
-
LiDAR Expansion Into Defense Market Keeps Innoviz Growth Narrative Intact Despite Revenue Decline (INVZ)
Innoviz reaffirmed its 2026 outlook while highlighting new defense and autonomous driving opportunities, even as first-quarter revenue fell sharply year over year. Key Investor Takeaways Why Innoviz Stock Is in Focus Innoviz reported first-quarter 2026 revenue of $7.1 million, down from $17.4 million in the same period last year. The company attributed the decline partly…
-
Cargo and Vehicle Inspection Order Adds New Government Business for OSI Systems (OSIS)
A new $15 million government task order expands OSI Systems’ security backlog and reinforces demand for its cargo and vehicle inspection technologies. Key Investor Takeaways Why OSI Systems Stock Is in Focus OSI Systems announced that its Security division received a task order worth approximately $15 million from a U.S. government customer. Under the agreement,…
-
Regenxbio Shares Rise After Positive Duchenne Trial Results
Regenxbio (NASDAQ:RGNX) shares gained more than 4% in premarket trading Thursday after investors focused on encouraging clinical trial results for the company’s Duchenne muscular dystrophy therapy, despite weaker-than-expected quarterly financial results. Earnings and Revenue Miss Expectations Regenxbio reported a first-quarter loss of $1.72 per share, wider than analyst expectations of a $1.34 loss per share.…
-
Biogen Shares Surge After Positive Mid-Stage Alzheimer’s Trial Results
Biogen (NASDAQ:BIIB) shares jumped 10% on Thursday after the company released encouraging Phase 2 data for diranersen, its experimental Alzheimer’s treatment targeting tau protein accumulation. The results came from the company’s CELIA study, which evaluated the therapy in patients with early-stage Alzheimer’s disease. Trial Shows Reductions in Tau Pathology Biogen said diranersen produced significant reductions…
-
Intuitive Machines Shares Slip After Revenue Miss Despite Record Quarter
Intuitive Machines (NASDAQ:LUNR) shares fell more than 3% in premarket trading Thursday after the company reported first-quarter revenue below Wall Street expectations, despite posting strong year-on-year growth and record operational metrics. Revenue Misses Forecasts as Loss Widens The company reported first-quarter revenue of $186.7 million, missing analyst expectations of $200.12 million. Revenue nevertheless nearly tripled…
-
CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance
CorMedix Therapeutics (NASDAQ:CRMD) shares surged 8% in premarket trading Thursday after the company raised its full-year outlook despite reporting quarterly earnings slightly below analyst expectations. Revenue Surges More Than 200% Year-on-Year CorMedix posted adjusted earnings per share of $0.43 for the first quarter, narrowly missing analyst expectations of $0.45 by $0.02. Revenue reached $127.4 million,…
-
Klarna Shares Surge After Strong First-Quarter Earnings Beat
Klarna Group (NYSE:KLAR) shares jumped more than 13% in premarket trading Thursday after the company reported first-quarter results that exceeded Wall Street expectations, supported by strong transaction growth and improving profitability. Revenue and GMV Growth Outpace Expectations Klarna posted an adjusted loss of -$0.01 per share for the quarter, significantly better than analyst forecasts for…
-
Nova Shares Rise After Record Quarter and Strong Outlook
Nova Measuring Instruments (NASDAQ:NVMI) shares climbed more than 3% in premarket trading Thursday after the company reported first-quarter results ahead of analyst expectations and issued stronger-than-expected guidance for the current quarter. Revenue and Earnings Reach Record Levels Nova posted adjusted earnings per share of $2.33 for the first quarter, exceeding analyst forecasts of $2.19 by…
-
Aya Gold & Silver Shares Rise After Record Revenue Beats Expectations
Aya Gold & Silver (NASDAQ:AYA) shares advanced more than 2% in premarket trading Thursday after the company reported first-quarter results highlighted by record revenue and sharply higher profitability. The mining company posted revenue of $117.3 million for the quarter ended March 31, 2026, representing a 247% increase from the same period last year. Higher Silver…